FDA approves breakthrough cancer drug months ahead of schedule: ‘Unprecedented results’

The U.S. Food and Drug Administration has approved a breakthrough drug for the most common form of pancreatic cancer more than six months ahead of schedule, offering what officials described as unprecedented survival rates for patients with limited options.